This award recognises the deeply embedded working relationship between a research organisation and business that delivers significant commercial value for New Zealand.
Partnering on long term and higher risk research projects to address significant, global diagnostic health problems
The University of Canterbury and Canterbury Scientific have successfully collaborated on projects to improve diagnosis of complications arising from diabetes. These collaborations have grown into a strong partnership addressing diagnostic health issues in diabetes, preeclampsia, and hypertension with an aim of developing new biotechnology products.
Our partnership supports Canterbury Scientific’s R&D challenges and goals, provides a clear path to market for new IP developed at the University of Canterbury and engages undergraduate and postgraduate students to provide them with relevant, industry experience and encourage entrepreneurial thinking at the University of Canterbury.
Canterbury Scientific develops and produces the highest quality freeze-dried and ready-to-use liquid haemoglobin controls available. Its major product, the haemoglobin A1c (HbA1c) control, is relied on by tens of thousands of people around the world to help manage their diabetes.
